MEDIPOST Co. Ltd Market Cap ($88.80 Million)
Market Cap & Net Worth: MEDIPOST Co. Ltd (078160)
MEDIPOST Co. Ltd market cap. MEDIPOST Co. Ltd (KQ:078160) has a market capitalization of $88.80 Million (₩131.04 Billion) as of November 4, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #19444 globally and #969 in its home market, demonstrating a 2.77% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying MEDIPOST Co. Ltd's stock price ₩8520.00 by its total outstanding shares 15379800 (15.38 Million). Also see MEDIPOST Co. Ltd (078160) cash conversion ratio for how efficiently the company converts equity into cash flow.
MEDIPOST Co. Ltd Market Cap History (2015–2026)
MEDIPOST Co. Ltd market cap history from 2015 to 2026. Data shows change from $443.45 Million to $88.80 Million (-12.86% CAGR). Check 078160 share price today for real-time trading data and today's change.
Index Memberships
MEDIPOST Co. Ltd is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$203.83 Billion | 0.04% | #389 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$203.83 Billion | 0.04% | #389 of 1384 |
Weight: MEDIPOST Co. Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
MEDIPOST Co. Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how MEDIPOST Co. Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore 078160 year-over-year net asset growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.00x
MEDIPOST Co. Ltd's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $443.45 Million | $37.57 Billion | $2.78 Billion | 0.01x | 0.16x |
| 2016 | $248.75 Million | $28.65 Billion | -$5.37 Billion | 0.01x | N/A |
| 2017 | $535.98 Million | $42.25 Billion | -$949.87 Million | 0.01x | N/A |
| 2018 | $335.33 Million | $44.38 Billion | -$2.01 Billion | 0.01x | N/A |
| 2019 | $320.67 Million | $45.81 Billion | -$14.12 Billion | 0.01x | N/A |
| 2020 | $317.01 Million | $48.62 Billion | -$1.90 Billion | 0.01x | N/A |
| 2021 | $196.07 Million | $54.86 Billion | -$683.26 Million | 0.00x | N/A |
| 2022 | $136.52 Million | $64.20 Billion | $3.07 Billion | 0.00x | 0.04x |
| 2023 | $85.05 Million | $68.64 Billion | $5.84 Billion | 0.00x | 0.01x |
| 2024 | $120.07 Million | $70.66 Billion | -$62.52 Billion | 0.00x | N/A |
Competitor Companies of 078160 by Market Capitalization
Companies near MEDIPOST Co. Ltd in the global market cap rankings as of November 4, 2026. Also see total assets of MEDIPOST Co. Ltd for a full breakdown of the balance sheet.
Key companies related to MEDIPOST Co. Ltd by market ranking:
- Peptron Inc (KQ:087010): Ranked #8535 globally with a market cap of $1.01 Billion USD ( ₩1.49 Trillion KRW).
- Bioneer Corporation (KQ:064550): Ranked #19060 globally with a market cap of $98.39 Million USD ( ₩145.18 Billion KRW).
- Cell Biotech Co. Ltd (KQ:049960): Ranked #19941 globally with a market cap of $78.69 Million USD ( ₩116.11 Billion KRW).
- Macrogen Inc (KQ:038290): Ranked #20196 globally with a market cap of $73.75 Million USD ( ₩108.83 Billion KRW).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #8535 | Peptron Inc | KQ:087010 | $1.01 Billion | ₩96900.00 |
| #19060 | Bioneer Corporation | KQ:064550 | $98.39 Million | ₩6570.00 |
| #19941 | Cell Biotech Co. Ltd | KQ:049960 | $78.69 Million | ₩15040.00 |
| #20196 | Macrogen Inc | KQ:038290 | $73.75 Million | ₩10860.00 |
Market Capitalization of MEDIPOST Co. Ltd (2015–2026)
Market capitalization of MEDIPOST Co. Ltd from 2015 to today. Between 2015 and today, MEDIPOST Co. Ltd's market cap moved from $443.45 Million to $ 88.80 Million, with a yearly change of -12.86%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩88.80 Million | -53.16% |
| 2025 | ₩189.59 Million | +57.90% |
| 2024 | ₩120.07 Million | +41.18% |
| 2023 | ₩85.05 Million | -37.70% |
| 2022 | ₩136.52 Million | -30.37% |
| 2021 | ₩196.07 Million | -38.15% |
| 2020 | ₩317.01 Million | -1.14% |
| 2019 | ₩320.67 Million | -4.37% |
| 2018 | ₩335.33 Million | -37.44% |
| 2017 | ₩535.98 Million | +115.47% |
| 2016 | ₩248.75 Million | -43.90% |
| 2015 | ₩443.45 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of MEDIPOST Co. Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $88.80 Million USD |
| MoneyControl | $88.80 Million USD |
| MarketWatch | $88.80 Million USD |
| marketcap.company | $88.80 Million USD |
| Reuters | $88.80 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About MEDIPOST Co. Ltd
MEDIPOST Co., Ltd. provides stem cell therapeutic solutions to meet the unmet medical needs in South Korea and internationally. It operates CELLTREE, an umbilical cord blood bank; and offers cord blood banking services to treat various incurable diseases. The company also markets CARTISTEM for the treatment of repetitive and/or traumatic cartilage degeneration, including degenerative osteoarthrit… Read more